Build conviction in the science behind every deal
Every stage of the deal, faster. Replace fragmented workflows with a single system that surfaces what matters earlier.
See Prudentia in actionSee Prudentia in action- SOC II aligned
Today’s fragmented approach can’t keep up
More assets to evaluate, more markets to source from. The same team, and the same tools that weren't built for this volume.
Without Prudentia
“We had 60 inbound programs last quarter. We moved 12 forward.”
“We screen everything. We make faster calls on what’s worth pursuing.”
Without Prudentia
“We liked the asset. We couldn’t build the internal case for the number.”
“Every position we took at the table had evidence behind it.”
Without Prudentia
“We found the risk in due diligence. Three months in.”
“We stop pursuing the wrong deals before they cost us.”
Without Prudentia
“We had 60 inbound programs last quarter. We moved 12 forward.”
With Prudentia: “We screen everything. We make faster calls on what’s worth pursuing.”Without Prudentia
“We liked the asset. We couldn’t build the internal case for the number.”
With Prudentia: “Every position we took at the table had evidence behind it.”Without Prudentia
“We found the risk in due diligence. Three months in.”
With Prudentia: “We stop pursuing the wrong deals before they cost us.”Manage your end-to-end deal pipeline
One system from sourcing to decision.
Centralize inbound and sourced opportunities across indications in one system.
Continuous drug assessment and deal diligence in a single platform
From early-stage programs to late-stage deals, evaluate every asset with a reproducible, evidence-based approach.
Screen opportunities with speed and consistency
Connect to all data in one place
Scale dealmaking with faster, more rigorous scientific assessment
Consider the full competitive landscape
Model valuations with confidence
0% alignment with manual pharma diligence assessments
Extend your experts’ judgement - keeping them in the loop while surfacing signals earlier.
A trusted third party between buyer and seller
Life sciences dealmaking involves some of the most sensitive data in the industry. Prudentia operates as the connective intelligence layer between pharma, biotech, VDR, and deal team, with every role bounded and every handoff disclosed.
Visit our Trust CenterVisit our Trust Center- SOC II aligned
- AWS-hosted
Secure Private Infrastructure
Single-tenant deployment with your data siloed and never shared across customers
Granular access controls
SSO integration with granular access controls and permissions
Data protected end-to-end
Encryption at rest and in transit, with complete audit trails
Built-in compliance
Your data is never used to train models, aligned with ISO/IEC 42001:2023
From asset profile to first deal conversation.
Five steps to a transaction-ready asset.
Corporate verification, KYB and signatory checks.
VerifyCorporate verification, KYB and signatory checks.
ProfileDrop a website, deck, or VDR. Prudentia abstracts the asset.
ConfirmReview what was extracted. Edit, approve, and lock.
PrioritizeChoose your objective: exploring, licensing, or M&A.
ShareEvaluate, value, and benchmark. Then share with vetted pharma BD on your terms.
Prudentia in practice
Identifying unseen risk before investor conversations
A CNS biotech preparing for its first institutional raise used Prudentia to assess its lead asset. By combining internal data with external evidence, the team uncovered critical regulatory strategy and preclinical safety risks, in addition to suboptimal portfolio prioritization strategy. Early identification of these risks allowed them to revisit their strategy and refine how the asset would be presented before engaging investors.
Identified previously unknown scientific risk
Reprioritized lead program, indication, and development strategy
Strengthened investor positioning across the full portfolio
Maintaining a clear view of a fast-moving competitive landscape
A clinical-stage immunology biotech used Prudentia to assess its asset and monitor a rapidly evolving global competitive landscape, including emerging companies in the space. Instead of relying on fragmented sources and manual tracking, the team built a continuously updated view of competitor activity and benchmarked their asset across both in-market and emerging programs.
Built a unified, global view of competitor activity
Benchmarked asset against peers with consistent criteria
Strengthened positioning in external partner discussions
Is your asset being evaluated through Prudentia?
- Your data is isolated and never shared across customers or used to train models.
- You control access and can revoke it at any time, with a complete audit trail.
- Every handoff between pharma, your VDR, and Prudentia is disclosed. Each party’s role is bounded.
- Pharma reaches conviction faster. You spend less time in limbo.